Graziella Filippini
Overview
Explore the profile of Graziella Filippini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1948
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Filippini G, Kruja J, Del Giovane C
Cochrane Database Syst Rev
. 2025 Mar;
3:CD013874.
PMID: 40066932
Background: Multiple sclerosis (MS) is the most common neurological cause of disability in young adults. Off-label rituximab for MS is used in most countries surveyed by the International Federation of...
2.
Ridley B, Nonino F, Baldin E, Casetta I, Iuliano G, Filippini G
Cochrane Database Syst Rev
. 2024 Dec;
12:CD015005.
PMID: 39651635
Background: Multiple sclerosis (MS) is an immune-mediated, chronic, inflammatory demyelinating disease of the central nervous system, impacting around 2.8 million people worldwide. Characterised by recurrent relapses or progression, or both,...
3.
Ridley B, Minozzi S, Gonzalez-Lorenzo M, Del Giovane C, Piggott T, Filippini G, et al.
Cochrane Database Syst Rev
. 2024 Sep;
9:CD015443.
PMID: 39254048
Background: In recent years a broader range of immunomodulatory and immunosuppressive treatment options have emerged for people with progressive forms of multiple sclerosis (PMS). While consensus supports these options as...
4.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, et al.
Cochrane Database Syst Rev
. 2024 Jan;
1:CD011381.
PMID: 38174776
Background: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biological agents. Although each one of these therapies reduces relapse...
5.
Tramacere I, Virgili G, Perduca V, Lucenteforte E, Benedetti M, Capobussi M, et al.
Cochrane Database Syst Rev
. 2023 Nov;
11:CD012186.
PMID: 38032059
Background: Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and...
6.
Lombardi G, Chipi E, Arenella D, Fiorani A, Frisoni G, Linarello S, et al.
Front Psychiatry
. 2022 Dec;
13:1050583.
PMID: 36506451
Introduction: Timely detection of cognitive decline in primary care is essential to promote an appropriate care pathway and enhance the benefits of interventions. We present the results of a study...
7.
Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K
Cochrane Database Syst Rev
. 2022 May;
5:CD013444.
PMID: 35510826
Background: Spasticity and chronic neuropathic pain are common and serious symptoms in people with multiple sclerosis (MS). These symptoms increase with disease progression and lead to worsening disability, impaired activities...
8.
Tondo G, Boccalini C, Vanoli E, Presotto L, Muscio C, Ciullo V, et al.
Neurology
. 2022 Apr;
99(3):e258-e269.
PMID: 35487700
Background And Objective: This was a multicenter study aimed at investigating the characteristics of cognitive decline, neuropsychiatric symptoms, and brain imaging in individuals with subjective cognitive decline (SCD) and subtle...
9.
Celani M, Nonino F, Mahan K, Orso M, Ridley B, Baldin E, et al.
Mult Scler Relat Disord
. 2022 Mar;
60:103688.
PMID: 35245817
Background: Eliciting the research priorities of people affected by a condition, carers and health care professionals can increase research value and reduce research waste. The Cochrane Multiple Sclerosis and Rare...
10.
Piggott T, Nonino F, Baldin E, Filippini G, Rijke N, Schunemann H, et al.
Mult Scler J Exp Transl Clin
. 2021 Dec;
7(4):20552173211051855.
PMID: 34900327
Background: A total of 2.8 million people are living with multiple sclerosis and due to disparities in access to medicines, the ability to treat this condition varies widely. Off-label disease-modifying...